secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-114996
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track
--------------------------------------------------------------------------------

- Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.
- Net loss of $44.2M ($0.76 per share) vs $40.9M loss ($0.79 per share) in Q3 2022.
- Phase 3 hypothalamic obesity trial expects full enrollment by end of 2023; 25.5% mean BMI reduction at 1 year in long-term extension (n=12).
- Cash & investments $299.3M as of Sep 30, 2023, sufficient to fund operations into 2026.
- Company expects 2023 Non-GAAP operating expenses $210M-$220M (R&D $125M-$130M, SG&A $85M-$90M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/0001104659-23-114996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/tm2329850d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer